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The present study examined the relationship between methylation of five genes (p16
INK4a, RASSF1A, APC, RARb and CDH13) and
patient survival in 351 cases of surgically resected lung cancers. While there was no relationship between the other genes and survival,
p16
INK4a methylation was significantly related to unfavourable prognosis in lung adenocarcinomas.
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Lung cancer is the leading cause of cancer deaths in the world.
Human lung cancers are classified into two major histologic types,
small-cell lung cancer (SCLC) and non-small-cell lung cancer
(NSCLC), the latter consisting of several subtypes. Previously,
squamous cell carcinoma was the predominant form of NSCLC,
but in the last few decades it has been replaced by adenocarci-
noma. Moreover, adenocarcinoma is the most common type of
lung cancer in women, never smokers and young subjects.
Aberrant methylation of CpG islands in the promoter region of
tumour suppressor genes (TSGs) and tumour-related genes has
become established as the major mechanism for gene silencing
(Baylin et al, 1998). Inactivation of TSGs by DNA methylation is
regarded as one of the fundamental processes for the development
of human malignant tumours, including lung cancers (Zochbauer-
Muller et al, 2001). We studied the methylation status of five genes,
p16
INK4a, RASSF1A, APC, RARb and CDH13, that are frequently
methylated in lung cancers and that are considered to play an
important role in the molecular pathogenesis of lung cancers
(Toyooka et al, 2001b). We previously reported that smoke
exposure, histologic type and geography-related differences in the
methylation profiles of NSCLC (Toyooka et al, 2003). Some reports
have described that methylation of specific TSGs are negative
prognostic factors for lung cancer (Tang et al, 2000; Burbee et al,
2001). In this study, we collected the survival data of 351 cases of
NSCLCs and correlated the methylation status of five genes
(p16
INK4a, RASSF1A, APC, RARb and CDH13) with clinicopatho-
logical factors to investigate the effect of methylation of five genes
on the survival of patients undergoing curative intent surgical
resections for lung cancer.
MATERIALS AND METHODS
We studied frozen specimens of 351 tumours stored at  801C
obtained from Japanese patients with primary NSCLCs treated by
curative intent surgical resection between 1993 and 2000 in our
institutions. The patients consisted of 234 males and 117 females
and their median age was 65 years. Most of the tumours (325, 93%)
were adenocarcinomas (199, 57%) or squamous cell carcinomas
(126, 36%), while the remainder consisted of 19 large-cell
carcinomas, six adenosquamous cell carcinomas and one un-
classified type. In all, 169 patients had stage I disease, 60 stage II,
122 stage III. A total of 252 patients (72%) were ever smokers with
a median smoke exposure of 45.9 pack years and 99 never
smokers. Institutional Review Board permission and informed
consent were obtained at each collection site.
Genomic DNA was isolated from frozen tumour tissue by SDS/
proteinase K (Life Technologies Inc., Rockville, MD, USA)
digestion, phenol–chloroform extraction and ethanol precipita-
tion. The methylation status of five genes reported to be frequently
methylated and silenced in tumour but not in nonmalignant lung
tissues (p16
INK4a, RASSF1A, APC, RARb and CDH13) (Toyooka
et al, 2003, 2004) was determined by methylation-specific PCR
(polymerase chain reaction) (MSP) assay using gene-specific
primers (Herman et al, 1996; Cote et al, 1998; Tsuchiya et al,
2000; Burbee et al, 2001; Toyooka et al, 2001a). Briefly, 1mgo f
genomic DNA was modified by sodium bisulphite, which converts
all unmethylated cytosines to uracils residues while methylated
cytosines remain unchanged. Polymerase chain reaction amplifica-
tion was performed with sodium bisulphate-treated DNA as
template as described previously (Herman et al, 1996). The MSP
assays were sensitive enough to detect one methylated allele in the
presence of 10
3–10
4 unmethylated alleles (Toyooka et al, 2003).
DNA from peripheral blood lymphocytes and buccal mucosa
brushes, each from 10 of nonsmoking healthy subjects, along with
water blanks were used as negative controls for the methylated
genes. DNA from lymphocytes healthy volunteer artificially
methylated by treatment with Sss1 (New England BioLabs, Beverly,
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sMA, USA) and then subjected to bisulphite treatment was used as a
positive control for methylated alleles. Polymerase chain reaction
products were visualised on 2% agarose gels stained with ethidium
bromide. Results were confirmed by repeat MSP assays after an
independently performed bisulphite treatment.
The overall survival was calculated from the date of surgery until
the date of death or the last follow-up. Univariate analysis of
overall survival was carried out by the Kaplan–Meier method
using the log-rank test. Multivariate overall survival analysis was
carried out by Cox’s proportional-hazards model. The stepwise
procedure was used to select independent variables with backward
elimination method with P-values of entry of 0.10 and rejection of
0.12. All data were analysed with StatView for Windows (SAS
Institute Inc., Cary, NC, USA).
RESULTS
The rates of methylation of five genes were determined in
351 cases of NSCLCs. Aberrant methylation was detected
in 86 (25%) of 351 cases for p16
INK4a, 120 cases (34%) for
RASSF1A, 131 cases (37%) for APC, 98 cases (28%) for RARb
and 104 cases (30%) for CDH13. We correlated the methyla-
tion status of five genes and clinicopathological factors
including gender, age, smoking status, histological differentiation
and TNM stage with prognosis for patient. The analysis was
performed on all 351 cases, and the major histological
subtypes adenocarcinomas and squamous cell carcinomas. As
adenocarcinomas are the predominant form of lung cancer in
never smokers, the percentage of adenocarcinoma patients
Table 1 Univariate and multivariate overall survival analysis (a) of all cases of lung adenocarcinomas and (b) 105 cases of stage I lung adenocarcinomas
P-value
Variable Subset No. Univariate
a Multivariate
b
(a)
Gender Male 104 0.092 NS
Female 95
Age (years) o65 115 0.15 0.069
654 84 (RR 1.46; 95% CI, 0.98–2.21)
Smoking status Ever smoker 110 0.11 NS
Never smoker 89
Differentiation Poor 41 0.15 NS
Moderate 98
Well 60
T stage T3 and 4 45 0.0002 0.006
T1 and 2 154 (RR 1.87; 95% CI, 1.20–2.92
N +7 8 o0.0001 o0.0001
  121 (RR 4.60; 95% CI, 3.00–7.05)
Stage I and II 130 o 0.0001 NS
III 69
p16
INK4a (M) + 33 0.020 0.019
  166 (RR 1.82; 95% CI, 1.10–3.00)
RASSF1A (M) + 69 0.16 NS
  130
APC (M) + 88 0.33 NS
  111
RARb (M) + 65 0.28 NS
  134
CDH13 (M) + 63 0.26 NS
  136
(b)
Gender Male 47 0.60 NS
Female 58
Age (years) o65 59 0.08 NS
654 46
Smoking status Smoker 52 0.33 NS
Never smoker 53
Differentiation Poor 20 0.58 NS
Moderate 43
Well 42
T stage T1 64 0.19 NS
T2 41
p16
INK4a (M) + 18 0.022 0.022
  87 (RR 2.57; 95% CI, 1.15–5.76)
RASSF1A (M) + 33 0.22 NS
  72
APC (M) + 46 0.091 NS
  59
RARb (M) + 29 0.92 NS
  76
CDH13 (M) + 34 0.72 NS
  71
M¼methylated; RR¼risk ratio; CI¼confidence interval; NS¼not selected in stepwise Cox’s proportional regression model.
aAnalysis with log-rank test.
bAnalysis with stepwise
Cox’s proportional-hazards regression model.
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swho smoked (55%) is lower than the figure for the overall patient
population (72%).
With regard to patient prognosis, there was no gene that was
correlated with survival in all cases or squamous cell carcinomas.
However, methylation of only one gene, p16
INK4a, was associated
with poor survival by Kaplan–Meier survival analysis (P¼0.020)
in adenocarcinoma (Table 1a and Figure 1). The results of
univariate and multivariate survival analysis for all variables are
shown in Table 1a. Besides p16
INK4a methylation, T stage
(P¼0.0002), lymph node status (Po0.0001) and disease stage
(Po0.0001) were correlated with poor prognosis on univariate
analysis (Table 1a). On multivariate analysis, p16
INK4a methylation
(RR¼1.82, 95% CI¼1.10–3.00, P¼0.019), T stage (RR¼1.87,
95% CI¼1.20–2.92, P¼0.006) and lymph node status (RR¼4.60,
95% CI¼3.00–7.05, Po0.0001) were independently associated
with adverse prognosis. Since a previous study indicated that
RASSF1A methylation was significantly related to poor prognosis
in stage I adenocarcinoma (Tomizawa et al, 2002), we analysed our
105 cases of stage I adenocarcinoma (Table 1b). Of the variables,
only p16
INK4a methylation was significantly related to unfavourable
survival by univariate and multivariate analysis in this cohort
(RR¼2.57, 95% CI¼1.15–5.76, P¼0.022). There was no relation-
ship between RASSF1A methylation (P¼0.22) and survival in
stage I adenocarcinoma or in all cases of adenocarcinomas
(P¼0.16) (Figure 1).
DISCUSSION
Using newer molecular biology technologies, many studies for
genetic abnormality of lung cancers have been investigated in
cancer pathogenesis and for their effects on clinical outcome.
Among the frequent genetic changes in lung cancer, abnormality
of p53 or K-ras has been extensively studied (Fukuyama et al, 1997;
Mitsudomi et al, 2000) including its significant association with
prognosis. Studies on the relationship between epigenetic changes
and patient outcome are of more recent origin. In our analysis,
only p16
INK4a methylation of the five genes that were frequently
methylated in lung cancer was significantly correlated with poor
prognosis in patients with lung adenocarcinoma. Furthermore,
p16
INK4a methylation, along with lymph node status and T stage,
was an independent prognostic factor by multivariate analysis. The
p16
INK4a protein controls the transition from the G1 phase to the S
phase in the cell cycle by inhibiting the phosphorylation of the
retinoblastoma protein (Weinberg, 1995). Loss of p16
INK4a
expression is frequently observed in lung cancers (Kratzke et al,
1996), and while inactivation may occur by other mechanisms such
as point mutations or homozygous deletions, aberrant methylation
is the most frequent method. Our results are consistent with other
reports that loss of p16
INK4a expression was correlated with poor
prognosis (Kratzke et al, 1996; Kawabuchi et al, 1999; Niklinski
et al, 2001). In addition, Kim et al (2001) reported that p16
INK4a
methylation was a risk factor predicting shorter survival after
surgery. Reports with regard to RASSF1A are more contradictory
(Burbee et al, 2001; Tomizawa et al, 2002; Endoh et al, 2003). We
have previously reported an association between RASSF1A
methylation and poor survival in resected Australian NSCLC cases
(Burbee et al, 2001). In our present much larger study from
Japanese cases, we were unable to demonstrate a relationship
between RASSF1A methylation and survival despite analysis of the
various subgroups. With regard to this issue, Tomizawa et al
(2002) pointed out that RASSF1A methylation was correlated with
poor prognosis in NSCLC patients at stage I. On the other hand,
Endoh et al (2003) reported that there was no correlation. Some of
these differences may be due to geographic, stage, subtype or other
variables.
Our study represents the largest study correlating methylation
and prognosis in lung cancer, and confirms and extends previous
reports that p16
INK4a inactivation is a negative prognostic factor
for NSCLC.
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Figure 1 Relationship between methylation status and patient survival by Kaplan–Meier method. (A) Survival curves by methylation status of p16
INK4a in
all cases. (B) Survival curves by methylation status of RASSF1A in all cases. (C) Survival curves by methylation status of p16
INK4a in all adenocarcinoma cases.
(D) Survival curves by methylation status of RASSF1A in all adenocarcinoma cases. The resulting curves were compared using log-rank test. M, methylated
group; NM, not methylated group.
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